Clinical Trial Update: Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating nivolumab plus ipilimumab with immunostimulatory embolization for stage IV renal cell carcinoma with an unresected primary has been t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Renal Cell Carcinoma, Renal Cell Carcinoma Stage IV | Phase 1 | Status: TERMINATED